SutroVax announced the appointment of Jane Wright-Mitchell as General Counsel and promotion of Elaine Sun to Chief Strategy Officer and Chief Financial Officer. Wright-Mitchell brings extensive experience in legal, regulatory and compliance across the pharmaceutical and healthcare industries, including licensing and corporate transactions, clinical trials, manufacturing, and intellectual property matters. She has previously served as chief legal officer, corporate secretary and chief compliance officer at AcelRx Pharmaceuticals, Inc; associate general counsel at Mesoblast Inc., assistant general counsel at Purdue Pharma, L.P. and associate general counsel at Neurogesx, Inc. Sun has served as Chief Financial Officer for SutroVax since January 2017. Her expanded role will include responsibility for SutroVax's financial, corporate development and strategy functions.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
VAXCYTE, INC. 
